Our study suggests that this may occur through a mechanism involving the induction of hypertension by oral axitinib, as well as MMP-9 degradation and the intravenous pembrolizumab destruction of elastin and collagen in the aortic wall. The gene discussed is ELN; the disease is hypertensive disorder.